The effects of S-allylmercaptocaptopril, the synthetic product of allicin and captopril, on cardiovascular risk factors associated with the metabolic syndrome
To access this article, please choose from the options below
PII: S0021-9150(05)00211-X
doi:10.1016/j.atherosclerosis.2005.03.009
© 2005 Elsevier Ireland Ltd. All rights reserved.
